Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2010

View Archived Issues

LMV-601 is potently active against HSV and HPV in preclinical studies

Neutrophil elastase inhibitor AZD-9668 shows promise in COPD

Tuberculosis candidate PNU-100480 is well tolerated in healthy volunteers

Pfizer discloses new activators of glucokinase

FDA provides guidance to Celsion for ThermoDox NDA

SNPs in PIK3C2B gene correlate with risk of Parkinson's disease

B-27-PD enters phase I/II trial in chronic noninfectious uveitis

BioRelix and Merck & Co. subsidiary partner to identify antibacterial drug candidates

Artemether sublingual spray is safe and efficacious in children with severe malaria

Cosmo Pharma's CB-03-01 effective in proof-of-concept alopecia study

FDA orphan drug status for rozrolimupab in immune thrombocytopenia

FDA grants orphan drug status to Prolor's longer-acting human growth hormone

Viralytics advances phase I trial of coxsackievirus A21

Bionomics receives approval for two phase Ib trials of BNC-210 in France

Meda completes acquisition of Alaven

Daiichi Sankyo discovers new PPAR-gamma agonists

Starpharma and Lilly collaborate on dendrimer-drug conjugate development

UCB patents new inhibitors of PI3K isoforms

U.S. researchers claim new DNA topoisomerase 1 inhibitors

Flu vaccine LIQ-001 advances to clinic in phase I trial

Phase III trial of aripiprazole in schizophrenia meets efficacy criteria

Akebia Therapeutics presents data from phase IIa AKB-6548 trial

Japanese scientists disclose new diagnostics for Alzheimer's disease

Altravax receives NIH grants for research on vaccines for HIV-1

Johnson & Johnson to acquire all outstanding shares of Crucell

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...